The Prevalence and Molecular Landscape of Lynch Syndrome in the Affected and General Population
Cancers · 18.07.2023 · 15 (14) · 3663
DOI: 10.3390/cancers15143663 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.07.2023. Verfasst von Laura Roht und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Estonian Research Council, EIT Health BRIGHT innovation activity, European Commission.
Abstract (Originalsprache)
Background
Lynch syndrome (LS) is the most frequent genetically pre-disposed colorectal cancer (CRC) syndrome, accounting for 2–3% of all CRC cases. In Estonia, ~1000 new cases are diagnosed each year. This retroactive and prospective study aimed to estimate the prevalence of LS and describe disease-causing variants in mismatch repair (MMR) genes in a diagnostic setting and in the Estonian general population.
Methods
LS data for the diagnostic cohort were gathered from 2012 to 2022 and data for the general population were acquired from the Estonian Biobank (EstBB). Furthermore, we conducted a pilot study to estimate the improvement of LS diagnostic yield by raising the age limit to >50 years for immunohistochemistry analysis of MMR genes.
Results
We estimated LS live birth prevalence between 1930 and 2003 in Estonia at 1:8638 (95% CI: 1: 9859–7588). During the study period, we gathered 181 LS individuals. We saw almost a six-fold increase in case prevalence, probably deriving from better health awareness, improved diagnostic possibilities and the implementation of MMR IHC testing in a broader age group.
Conclusion
The most common genes affected in the diagnostic and EstBB cohorts were MLH1 and PMS2 genes, respectively. The LS diagnosis mean age was 44.8 years for index cases and 36.8 years (p = 0.003) for family members. In the MMR IHC pilot study, 29% had LS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.
- Department of Clinical Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.
- Department of Laboratory Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.
- Estonian Biobank, Institute of Genomics, University of Tartu, 51010 Tartu, Estonia.
- Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, Estonia.
- Asper Biogene LLC, 50410 Tartu, Estonia.
ORCID-Profile: Katrin Õunap, Tiina Kahre
Förderung
- Estonian Research Council
- EIT Health BRIGHT innovation activity
- European Commission
Zitieren
APA
Roht, L., Laidre, P., Tooming, M., Tõnisson, N., Nõukas, M., Nurm, M., Estonian Biobank Research Team, Roomere, H., Rekker, K., Toome, K., Fjodorova, O., Murumets, Ü., Šamarina, U., Pajusalu, S., Aaspõllu, A., Salumäe, L., Muhu, K., Soplepmann, J., Õunap, K., & Kahre, T. (2023). The Prevalence and Molecular Landscape of Lynch Syndrome in the Affected and General Population. Cancers, 15(14), 3663. https://doi.org/10.3390/cancers15143663
Vancouver
Roht L, Laidre P, Tooming M, Tõnisson N, Nõukas M, Nurm M, et al. The Prevalence and Molecular Landscape of Lynch Syndrome in the Affected and General Population. Cancers. 2023;15(14):3663. doi:10.3390/cancers15143663
BibTeX
@article{Roht2023,
author = {Roht, Laura and Laidre, Piret and Tooming, Mikk and Tõnisson, Neeme and Nõukas, Margit and Nurm, Miriam and Estonian Biobank Research Team and Roomere, Hanno and Rekker, Kadri and Toome, Kadri and Fjodorova, Olga and Murumets, Ülle and Šamarina, Ustina and Pajusalu, Sander and Aaspõllu, Anu and Salumäe, Liis and Muhu, Kristina and Soplepmann, Jaan and Õunap, Katrin and Kahre, Tiina},
title = {The Prevalence and Molecular Landscape of Lynch Syndrome in the Affected and General Population},
journal = {Cancers},
year = {2023},
volume = {15},
number = {14},
pages = {3663},
doi = {10.3390/cancers15143663}
}
EUVIMED